ClinicaliQ Trial Snapshot
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) — Recruiting • Phase I • Oncology • NCT07101328.
- LY4152199 is a novel investigational agent being evaluated for dose-optimisation, safety, and efficacy in patients with relapsed or refractory B-cell malignancies who have failed prior systemic treatment, addressing an unmet clinical need in heavily pre-treated populations.
- Eligible participants are adults with previously treated B-cell malignancies (including lymphomas and leukaemias) who have progressed despite or become intolerant to standard therapies, with continuation dosing available for responders.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
Eligibility Snapshot
- : * Must have a diagnosis of either follicular lymphoma or diffuse large B-cell lymphoma. * Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Estimated life expectancy of greater than or equal to (≥)12 weeks as judged by the Investigator. * Participants with select tumor types must have measurable or assessable disease as defined below: * Participants with lymphoma must have at least 1 bi-dimensionally measurable lesion or in the absence of measurable lymphadenopathy, documentation of bone marrow involvement. * Participants with Waldenstrom macroglobulinemia (WM) must have measurable disease, defined as the presence of serum IgM with a minimum IgM level of greater than (>)2 times (×) upper limit of normal (ULN) based on local laboratory testing. * Must be able to comply with inpatient/outpatient treatment, laboratory monitoring, and required clinic visits for the duration of trial participation. * Must have adequate organ function. Phase 1 Dose Escalation (Cohort A) Participants - Must have histologically confirmed relapsed/refractory B-cell malignancy. Phase 1 Dose Optimization (Cohort B) Participants - Must have histologically confirmed relapsed/refractory diffuse large B-cell lymphoma (DLBCL) de novo or transformed from follicular lymphoma (FL).
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.